Eli Lilly and Company - Total Cashflows From Financing Activities

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Total-Cashflows-From-Financing-Activities" stands at 0.4404 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.

Eli Lilly and Company's third quarter result of 0.531 Billion USD for the item "Total Cashflows From Financing Activities" represents an increase of 142.65 percent compared to it's second quarter result.

Also, Eli Lilly and Company's third quarter result of 0.531 Billion USD for the item "Total Cashflows From Financing Activities" represents an increase of 151.30 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 0.4404 Billion USD for the item "Total Cashflows From Financing Activities" represents an increase of 264.87 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an decrease of -4.56 Billion United States Dollars compared to the value the year prior.
The 1 year change is -4.56 Billion United States Dollars.
The 3 year change is 6.23 Billion United States Dollars.
The 5 year change is 3.40 Billion United States Dollars.
The 10 year change is 1.05 Billion United States Dollars.

The Serie's long term average value is -2.06 Billion United States Dollars. It's latest available value, on 09/30/2025, is 2.50 Billion United States Dollars higher, compared to it's long term average value.
The Serie's change in United States Dollars from it's minimum value, on 03/31/2022, to it's latest available value, on 09/30/2025, is +6.39 Billion.
The Serie's change in United States Dollars from it's maximum value, on 06/30/2024, to it's latest available value, on 09/30/2025, is -4.92 Billion.